September 26, 2025 7:50am

BREAKING: Core inflation – a measure excluding food and energy costs – ran at a 2.9% seasonally adjusted annual rate and 0.2% on a monthly basis; in line with expectation. All-items index showed an annual rate of 2.7% as well as a monthly gain of 0.3%, in line with expectations as well.

News: uniQure NV (QURE -$1.01 or -1.92% to $52.64) Prices public offering. Mesoblast (MESO; ASX: MSB) its allogeneic cell therapy products are “NOT” subject to tariffs

Pre-open signals: 1 Positive, 1 Negative with a weak pre-open

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

News: uniQure NV (QURE -$1.01 or -1.92% to $52.64) Prices $300 M public offering of 5,789,473 shares at a price of $47.50 per share, and warrants to purchase 526,316 of its shares; expecting $300 M in gross proceeds. Mesoblast (MESO; ASX: MSB) its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin products “NOT” subject to tariffs on imported branded or patented pharmaceutical products.

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short-term striving toward the near and longterm

 

Friday night’s … RMi Closing Bell: Riding the merry-go-round … https://www.regmedinvestors.com/articles/14123

Updated … RMi Research Note: Harvard Apparatus GT (OTCQB): Who is wasting lipstick on this pig? … https://www.regmedinvestors.com/articles/13812

 

Friday: The pre-open Dow futures are UP +0.46% or (+211 points), the S&P futures are UP +0.41% or (+27 points) and the Nasdaq futures are UP +0.41% or (+101 points)

  • Stock futures powered up after PCE release, Friday 9/26
  • European markets were higher, as the Stoxx Europe 600 Healthcare index experienced rocky trading in the morning, following president Trump announced a 50% tariff on medicine imports
  • Asia Pacific markets declined as shares of Asian pharmaceutical companies fell

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -173.96 points or -0.38%, the S&P closed DOWN -32.25 points or -0.50% while the Nasdaq closed DOWN -131.157 points or -0.50%
  • Wednesday: The Dow closed DOWN -171.50 points or -0.37%, the S&P closed DOWN -18.95 points or -0.28% while the Nasdaq closed DOWN -75.618 points or -0.34%
  • Tuesday: The Dow closed DOWN -88.76 points or -0.19%, the S&P closed DOWN -36.83 points or -0.65% while the Nasdaq closed DOWN -215.503 points or -0.95%
  • Monday: The Dow closed UP +66.27 points or +0.14%, the S&P closed UP +29.39 points or +0.44% while the Nasdaq closed UP +157.50 points or +0.70%
  • Week so far, the Dow has shed 0.8%, the S&P 500 is down nearly 0.9% and the Nasdaq has lost about 1.1%
  • Last week: The Dow was up +1%, the S&P 500 +1.2% and the Nasdaq +2.2%.

Economic Data Docket: Initial jobless claims, GDP (3rd estimate), Advanced U.S. trade balance in goods - Aug., Advanced retail inventories - Aug., Advanced wholesale inventories - Aug., Durable-goods orders - Aug., Durable-goods minus transportation and Existing home sales

 

Q3 – September, 1 holiday, 9 negative and 9 positive closes

  • August - 11 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I see red after as September continues to close with more econs coming and proximity to the Q’s end, along with the usual ups, downs and just plain uncertainties

Passing … as econs seem to dissolve share pricing or so it has!

With a few:

Vertex (VRTX) closed up +$5.25 with a positive +$0.63 or +0.16% pre-open

uniQure NV (QURE) closed up +$5.15 after Wednesday’s +$33.84 with a negative -$1.01 or -1.92% pre-open following offering announcement and its pricing

 

The BOTTOM LINE: “It’s always darkest before the pitch dark” …

The cell and gene therapy sector has responded in its usual alternating trend as I have written “econs have been poison” to our universe

  • Indexes fell for the 3rd day in a row
  • With the cell and gene therapy sector seeing a few too many fits and starts, so …

 

The cell and gene therapy sector responds in its usual alternating trends as I have written “econs have been poison” to our universe

Again, investors feel pain, “riding the skids of uncle algo and his electronic trading dwarfs” as the “the posse” alternate the cell and gene therapy sector’s being bought or sold into

 

September is in the front window: understand the sector “flow” of my 40 covered companies sshare pricing ...

  • 9/25 – Thursday closed negative with 8 positive, 30 negative and 2 flats
  • 9/24 – Wednesday closed positive with 28 positive, 11 negative and 1 flat
  • 9/23 – Tuesday closed negative with 7 positive, 32 negative and 1 flat
  • 9/22 - Monday closed positive with 31 positive, 9 negative and 0 flat

Last week:

  • 9/19 – Friday closed negative with 7 positive, 33 negative and 0 flat
  • 9/18 – Thursday closed positive with 33 positive, 6 negative and 1 flat
  • 9/17 – Wednesday closed negative with 10 positive, 30 negative and 0 flat
  • 9/16 – Tuesday closed positive with 29 positive, 9 negative and 2 flats
  • 9/15 – Monday closed negative with 17 positive, 22 negative and 1 flat

 

September has historically delivered pullbacks, yet, this year’s 2025 market has defied that pattern — climbing 35% since March with strong technical and fundamental tailwinds,

Q2 Earnings are in the rear-view mirror; we are about to start again … Q3!

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.